Frontlight ResearchEarly access
Active, not recruitingNo phase
Autus Valve Continued Access Study (CAS)
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- Ann Arbor, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 4 people enrolled
- Started
- 27 Jul 2026
- Expected to end
- 30 Apr 2036
- Type of study
- Interventional
- Treatments tested
- Pulmonary Valve Replacement Surgery
- Record updated
- 20 October 2026
Who can take part
- Age
- 18 months to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (27)Hide the full registry criteria
Who can take part
- Age 18 months to 16 years
- Male or female
- Subject has a native or repaired right ventricular outflow tract
- Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon)
- Subject has at least one of the following echocardiographic findings:; Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg); Moderate or greater pulmonary regurgitation; Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation
- Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter)
- Subject and parent/legal representative, where appropriate, are willing to provide informed written consent
- Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits
Who cannot take part
- Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses
- Subject is participating in an investigational study of a new drug, biologic, or device at the time of study screening; -
- Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg)
- Subject has a known history of pulmonary atresia and major aortopulmonary collaterals
- Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics)
- Subject has active endocarditis or a history of infective endocarditis
- Subject has a known history of hypersensitivity to anticoagulants and antiplatelet drugs
- Subject has a known history of autoimmune disease or receives immunosuppressant and/or immunostimulant drugs, and the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes
- Subject needs emergency cardiac or vascular surgery or intervention
- Subject has a known history of renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease
- Subject has a known history of leukopenia (defined as a white blood cell [WBC] count <3.5 x 103/µL)
- Subject has a known history of acute or chronic anemia (defined as hemoglobin [Hgb] <10.0 g/dl or 6 mmol/L)
- Subject has a known history of thrombocytopenia (defined as platelet count <50 x 103/µL)
- Subject requires valve replacement in a non-pulmonary position
- Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years)
- Subject has significant peripheral pulmonary artery stenosis
- Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years
- Subject or parent/legal representative refuses blood transfusions
- Subject has medical, social, or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures
Where in United States
- University of Michigan/Mott Children's HospitalAnn Arbor, United States
About the trial
What the trial wants to find out
Prospective, single-arm, multi-center, continued access study of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implantation, at hospital discharge, 30 days, 6 months, and annually through 10 years.
Read full original descriptionShow less
The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject.
The group in the trial
- Autus Valve ArmTreatment being tested
Pulmonary Valve Replacement Surgery with the Autus Valve
Treatment: Pulmonary Valve Replacement Surgery
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Autus Size-Adjustable Valve for Surgical Pulmonary Valve Replacement Continued Access Study
- Record updated
- 20 October 2026